Mersana Therapeutics, Inc. License Agreements
7 Contracts & Agreements
- License, Development and Commercialization Agreement, dated July 9, 2015, by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A (Filed With SEC on May 9, 2023)
- Amendment No. 1 to the Amended and Restated Commercial License and Option Agreement, dated February 2, 2022, between the Company and Synaffix B.V (Filed With SEC on May 9, 2022)
- Amended and Restated Commercial License and Option Agreement, dated November 23, 2021, by and between Synaffix B.V. and Mersana Therapeutics, Inc (Filed With SEC on February 28, 2022)
- Commercial License and Option Agreement (Filed With SEC on August 7, 2020)
- First Amendment to the License, Development and Commercialization Agreement dated August 19, 2019, by and between Mersana Therapeutics, Inc. and Recepta Biopharma, S.A (Filed With SEC on November 6, 2019)
- CONFIDENTIAL LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between MERSANA THERAPEUTICS, INC. and RECEPTA BIOPHARMA S.A. (Filed With SEC on June 1, 2017)
- Second Amendment to the License, Development and Commercialization Agreement, dated September 28, 2021, by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A.... (Filed With SEC on November 9, 2021)
